Timeline

In 1987, UBC made a bold investment by establishing Canada's first interdisciplinary biotechnology unit. Dr. Michael Smith was named the founding Director of the Biotechnology Laboratory where he recruited some of the brightest minds. This unit quickly became a resource for the entire university, encouraging biotechnology advancements across the campus and in the wider scientific community.

Darlene Crowe joins the Biotechnology Laboratory as administrative staff. She worked closely with Michael Smith, playing a foundational role in the creation of the organization, setting up the tenure and promotion structure for faculty and championing the novel aspects of the laboratory. Well-connected across UBC campus, Darlene was renowned for her exceptional organizational and creative problem-solving skills and was integral to the growth and development of the Biotechnology Laboratory over her 21-year tenure. 

Dr. Charles Haynes, a chemical engineer, was recruited to the Biotechnology Laboratory in 1993. The central objective of Dr. Haynes’ research program is to improve the understanding of the interfacial behavior of biomolecules and cellular systems and to use this fundamental knowledge to invent new technologies and instruments.

In 1993, Dr. Michael Smith received the Nobel Prize in Chemistry for his research on site-directed mutagenesis, a technique where a specific DNA sequence could be altered in a targeted manner. Smith shared the Prize with Dr. Kary Mullis for his invention of the PCR method. Smith's research opened the door to entirely new fields such as genetic engineering and synthetic biology. 

SonoSep Technologies Inc., a spin-out company from Dr. James Piret's lab and collaborators, developed a new cell separation device. Particulate material suspended in a fluid could be separated and recycled using the device's ultrasonic resonance wave. This research was outlined in Nature Biotechnology.

The Biotechnology Laboratory appoints Dr. Doug Kilburn as the new Director. He played an integral role in developing the associate member program and built key relationships with the genome sciences centre. Well-recognized and highly-reputable, Dr. Kilburn succeeded Dr. Michael Smith as the Director of the Biotechnology Laboratory.

In 1997, Dr. Phil Hieter joins the Biotechnology Laboratory. The Hieter lab develops and applies genetic and biochemical methodologies in the model organism, Saccharomyces cerevisiae (bakers yeast), to better understand the molecular components required for chromosome transmission. The overarching goal of the Hieter lab is to relate the work with yeast to human cancer. 

The Biotechnology Laboratory welcomes Dr. David Ng as the Director of the Advanced Molecular Biology Laboratory (outreach and science education component). Dr. Ng is a geneticist, science educator, science literacy academic, and faculty member. His current research interests involve concepts of science and creativity, as well as game-based learning of science concepts. 

In 2000, Dr. Jörg Bohlmann joins the Biotechnology Laboratory. Dr. Bohlmann's research involves the molecular biochemistry and biology of plant secondary metabolites, genomics of conifers, grapevines, and various medicinal plants, and plant defense against insects.

 In a research paper published in Nature Biotechnology, Dr. Wilfred Jefferies discovers a major class of tumors that lack expression of the transporters associated with antigen processing (TAP). Dr. Jefferies suggests that TAP should be considered for inclusion in cancer therapies as it is likely to provide a general method for increasing immune responses against tumors regardless of the antigenic complement of the tumor or the MHC haplotypes of the host.

In January 2001, Dr. Phil Hieter was appointed as the new Director of the Michael Smith Laboratories. He played a key role in the construction of the new building. Dr. Hieter succeeded Dr. Kilburn as the Director of the Biotechnology Laboratory.

In 2001, a Royal Society of Canada expert panel, chaired by Drs. Brian Ellis and Conrad Brunk, published Elements of Precaution: Recommendations for the Regulation of Food Biotechnology in Canada. This report was prepared by the Royal Society of Canada at the request of Health Canada Canadian Food Inspection Agency and Environment Canada.

The Biotechnology Laboratory welcomes Dr. Xin Li, an expert in plant immunity. Dr. Li's lab uses a combination of molecular genetics, biochemical, and genomics to understand the natural resistance mechanisms of plants against microbial pathogens including fungi, bacteria, and viruses.

In 2001, Drs. Terry Snutch and Brett Finlay were elected as Fellows into the Royal Society of Canada. The Royal Society of Canada is the recognized pre-eminent body of independent scholars, researchers and creative people in Canada whose Fellows comprise a collegium that can provide intellectual leadership for the betterment of Canada and the world.

Dr. Wilfred Jefferies and collaborators discovered that the iron transport protein, P97, acts as a molecular marker for Alzheimer's disease (AD). Previous research by Dr. Jefferies showed that iron levels were elevated in the brains of AD patients. Furthering this research, Dr. Jefferies and his collaboratories found that P97 was increased in the serum but not in various control groups, making it a potentially powerful biomarker for AD. This potential biomarker would allow for non-invasive medical testing for AD. This research was published in Frontiers in Bioscience. 

A spin-out from the labs of Drs. Brett Finlay and Robert Hancock, called Inimex Pharmaceuticals, focused on fighting superbugs with Innate Defense Regulators (IDRs). IDRs are drugs that selectively modulate the body's innate defenses without causing inflammation. Inimex Pharmaceuticals raised more than $28 million. 

As an emerging pandemic began sweeping the globe, Drs Brett Finlay, Marco Marra and their research teams worked around the clock to sequence the novel Severe Acute Respiratory Syndrome (SARS) virus in just six days. This impressive milestone paved the way for another enormous accomplishment – the development of three possible vaccines for SARS in under a year in collaboration with many other scientists as part of the SARS Accelerated Vaccine Initiative (SAVI) program. The innovative scientific approaches used to solve the SARS crisis would go on to inform the processes of combatting future pandemics like COVID-19 in 2020. 

In 2005, it was announced that Dr. Terry Snutch was awarded the CIHR Tier 1, Canada Research Chair in Biotechnology and Genomics - Neurobiology. Dr. Snutch's research demonstrates how various types of calcium channels are regulated by enzymes and by intracellular molecules called G-proteins. His studies hope to show how painkiller molecules (both natural opioids and synthetic painkillers such as morphine) work. Ultimately, his research will provide invaluable information to help other scientists design new calcium channel therapies for conditions including stroke, migraine, and epilepsy.

In April 2005, Dr. Brett Finlay was elected as a Fellow of the Canadian Academy of Health Sciences (CAHS), a national scientific organization founded by the Canadian Academy of Engineering, the Canadian Institute of Academic Medicine, and the Royal Society of Canada. The mission of CAHS is to provide a source of credible independent expert assessments on the sciences underlying pressing issues and matters of public interest and to provide a national and international scientific voice for Canada. Dr. Finlay was officially inducted in September 2005.

Neuromed Pharmaceuticals, a spin-out company led by Dr. Terry Snutch, signs the largest agreement in Canadian biotech history (potentially worth $500 million) with Merck & Co. for painkiller MK-6721. Dr. Snutch was the first scientist in the world to describe the molecular basis for calcium channels in the cardiovascular, endocrine, and nervous systems. 

Dr. Brett Finlay was appointed Officer of the Order of Canada in 2006.  The Order of Canada recognizes “a lifetime of outstanding achievement and merit of a high degree, especially in service to Canada or to humanity at large.” Dr. Finlay is highly respected for his body of work on the E. coli and Salmonella bacteria as well as the SARS virus. He has succeeded in developing practical solutions and productive partnerships to respond to public health threats. His innovative research, paired with his remarkable analytical and communication skills, has played a significant role in shaping Canada's evolving health policy.

Michael Smith Laboratories researchers, Drs. Jörg Bohlmann and Brian Ellis, are involved in decoding the first tree genome of the black cottonwood or Populus trichocarpa tree. The sequencing effort identified more than 45,000 putative protein-coding genes in the Populus genome. This groundwork may lead to the development of trees as an ideal “feedstock” for a new generation of biofuels such as cellulosic ethanol. The research was published in Science.

Dr. Joanne Fox completed her PhD in Genetics from UBC, and was then appointed Head of support and training at the UBC Bioinformatics Centre. She joined the Michael Smith Laboratories in 2007 as an Instructor where she was promoted through the ranks to Professor of Teaching. Dr. Fox is a science educator and outreach academic. She is involved in innovative teaching and learning initiatives and educational leadership activities, with specific areas of expertise in the first year experience, international education, program evaluation, and scientific communication. 

Dr. Brett Finlay awarded Order of British Columbia. The Order represents the highest form of recognition the Province can extend to its citizens in recognition of excellence in an endeavour benefiting the people of the Province or elsewhere.

Dr. Charles Haynes was elected as a Fellow into the Royal Society of Canada in 2007. Dr. Charles Haynes is an internationally recognized authority on downstream processing of biologic therapeutics at manufacturing scales.

A merger between the bioinformatics cluster and the proteomics cluster at UBC, created the Centre for High-Throughput Biology (CHiBi). This project was worked on for over five years by Phil Hieter, Brian Ellis, George Mackie, and Stephen Withers. CHiBi was an autonomous interdisciplinary research and graduate teaching unit with a focus on the application and development of high-throughput methods for the analysis of biological systems.  In 2008, Dr. Stephen Withers was appointed as the Director of CHiBi. Later in 2015, CHiBi merged with the Michael Smith Laboratories (formerly known as the Biotechnology Laboratory).

In 2008, Dr. James Kronstad was appointed to Director of the Michael Smith Laboratories. Dr. Kronstad helped double the size of the faculty by facilitating the merger of the Centre for High-throughput Biology (CHiBi) with the Michael Smith Laboratories. He also played a key role in recruiting high-profile researchers to the Michael Smith Laboratories.

Research by Dr. Brett Finlay has helped develop Econiche - the world’s first vaccine designed to reduce cattle shedding of a particularly dangerous strain of E. coli. Econiche was developed by the Canadian biopharmaceutical company Bioniche in partnership with UBC, the Alberta Research Council (ARC), and the University of Saskatchewan. Most strains of E. coli are harmless, but some can cause severe illness and even be fatal when ingested by humans from contaminated meat, vegetables or water. The vaccination of cattle can help reduce the risk of food and water contamination by a strain that is dangerous to humans: Escherichia coli O157:H7.

In 2009, Dr. Charles Haynes was announced as a Tier 1 Canadian Research Chair in Interfacial Biotechnology. As the holder of the Canada Research Chair in Interfacial Biotechnology, Dr. Haynes will explore the molecular basis of such interactions. He will then apply this fundamental knowledge to the design of natural or synthetic surfaces that will make it possible to analyze complex biosystems at the molecular level.

Initiated by Dr. Dave Ng, the Phylo trading card game started as an exercise in crowdsourcing, open access, and open game development to create a trading card game. This project has grown to broach elements of game-based science education, ecological literacy, and hackathon mechanics within the teaching community. Given its flexible and open workflow, Phylo has benefited from the input of many communities of expertise, and many collaborations (both formal and spontaneous) leading to a continually expanding resource that is under constant reiteration.

Dr. Thibault Mayor wins a Canadian Institutes of Health Research (CIHR) New Investigator Award. This award is considered to be one of the most prestigious awards in Canada. It supports researchers in the early stages of their career who have shown promise as independent investigators by providing assistance for them in establishing their program of research. Dr. Mayor's research aims to better understand how unwanted and aberrant proteins are eliminated from the cell.

In 2012, Dr. Thibault Mayor was awarded a Michael Smith Foundation for Health Research (MSFHR) Career Investigator Award for his research on the characterization of the formation of protein aggregates induced by the inhibition of the ubiquitin proteasome system. Dr. Mayor’s research aims to lead to a better understanding of the aggregation mechanism and identify novel targetable pathways to prevent formation or favor clearance of protein aggregates.

AbCellera Biologics Inc., a spin-out company from the Michael Smith Laboratories, is leading the industry in next-generation antibody therapies using new and innovative technology developed at UBC. Led by Dr. Carl Hansen, AbCellera is becoming one of the fastest-growing biotech companies in BC.

The genome of the mountain pine beetle – the insect that has devastated B.C.’s lodgepole pine forests – has been decoded by researchers from Dr. Jörg Bohlmann's lab and Canada’s Michael Smith Genome Sciences Centre. This is a first for the mountain pine beetle and only the second beetle genome ever sequenced. This research was published in Genome Biology.

Canadian and Swedish scientists today released genome sequences of two of the most economically important forest trees in the world. Dr. Jörg Bohlmann collaborated on this project to decode the spruce genome, Canada's most important forest tree. This research was published in Nature.

Darlene Crowe, first staff member hired by Michael Smith, retires. With the MSL since its inception (then called UBC’s Biotechnology Laboratory), Darlene played an essential role in the growth and success of the organization. Serving as lead administrator for four consecutive MSL Directors Drs. Michael Smith, Doug Kilburn, Phil Hieter and Jim Kronstad, Darlene’s contributions to the MSL were significant. Her impact on the laboratories is lasting and treasured. 

New research by Dr. Brett Finlay and collaborators find that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age. More than 300 families from across Canada participated in this research through the Canadian Healthy Infant Longitudinal Development (CHILD) Study. The discovery of the four microbial species that inhibits asthma opens the door to developing probiotic treatments for infants that can prevent asthma. The study was published in Science Translational Medicine.

Dr. Robin Turner and collaborators developed Process Analytical Technologies (PAT) based on Raman spectroscopy. Raman spectroscopy has many practical attributes that make it a promising PAT, such as its ability to be used nondestructively on live cells and is receptive to automated operation.

Co-founded by Drs. Brett Finlay and Bill Mohn, Microbiome Insights was a company created from an influx of demands for microbiome research. While working on their own research at UBC, Drs. Finlay and Mohn were inundated with so many testing requests that they barely had time to complete their own projects. They contacted Malcolm Kendal, with whom they had worked previously, and created Microbiome Insights shortly after.

Dr. Brett Finlay and collaborators have developed the first animal model for childhood malnutrition. This model replicates the imbalance of gut bacteria associated with the difficult-to-treat disease since malnutrition includes a variety of environmental factors. Their findings were published in Nature Communications.

The 14^th Human Proteome Organization World Congress was held in Vancouver, British Columbia from September 27th – 30th, 2015. Building on the success of the preceding Congresses in Sydney, Boston, Yokohama and Madrid, the theme of the 2015 meeting “Translating Proteomics and Allied-Omics to the Clinic” underpinned the need for collaboration and cooperation of individuals from a wide range of professional backgrounds. Dr. Thibault Mayor organized and hosted a HUPO workshop on post-translation modifications in the Advanced Molecular Biology Laboratory located in the Michael Smith Laboratories. 

Dr. Christian Kastrup and his lab have created a supercharged platelet that might be capable of healing major wounds, busting clots or blocking inflammation. Unlike most cells, platelets lack a nucleus and do not have DNA. The Kastrup lab discovered a method to inject the platelets with DNA and other ingredients needed to make RNA, creating the first platelets ever to have synthetic nuclei (RNA). This research was published in the journal Angewandte Chemie International Edition 

Dr. Cara Haney joins the Michael Smith Laboratories with an appointment at Microbiology & Immunology and is an Associate Member of the Botany Department. Utilizing the model plant Arabidopsis and its associated bacterial community, her research work is focused on delineating the genetic and environmental factors that shape the plant-microbiome interactions and influence the development and disease susceptibility in plants.

The first in situ analysis of red blood cell concentrate was conducted by Dr. Robin Turner, in collaboration with Dr. Michael Blades and Dr. Dana Devine. They used Raman spectroscopy to assess fitness of the blood cells for transfusion. This non-invasive method was outlined in a paper published in Analyst.

Dr. Brett Finlay co-authors, Let Them Eat Dirt, a book describing why dirt can be a child’s best friend. Dr. Finlay uses the latest research to highlight the critical role bacteria play in growing bodies. The book offers tips on how parents can ensure their kids get exposed to plenty of healthy bugs.

Dr. Brett Finlay and his collaborators showed that early life microbes related to asthma in Ecuadorian children are different than those found in Canadian children. Finlay and his colleagues found that while four gut bacteria play a role in preventing asthma in Canadian children, it was the presence of a microscopic yeast known as Pichia that was more strongly linked to asthma in Ecuadorian children. This research was presented at the 2017 annual meeting for Association for the Advancement of Science. 

Dr. Terry Snutch was inducted into the National Academy of Inventors at a ceremony at the John F. Kennedy Presidential Library and Museum on April 6, 2017. A rare honour, he is one of only three researchers in Canada inducted into the most recent cohort of Fellows. Dr. Snutch’s statement of induction notes the accolade is “in recognition of exceptional accomplishments in innovation and invention to the benefit of society.”

In June 2017, Dr. Peter Zandstra was appointed as the Director of the Michael Smith Laboratories. A pioneer in the field of stem cell bioengineering, Dr. Zandstra is known for applying engineering principles to stem cell biology. His research group aims to understand the complex communication networks between stem cells which has led to direct application to the fields of tissue and cellular engineering, gene therapy, and organ transplantation. 

In 2018, the Genetics Society of America announced that Dr. Philip Hieter was the recipient of the 2018 George W. Beadle Award. Geneticists across the model organism and human genetics communities recognize Hieter for his dedication to uniting human biologists with those who work on model organisms. His lab's contributions to the yeast community include physical mapping methods, synthetic lethality screen approaches for identifying cross-species candidate genes as potential cancer drug targets, and a widely used set of vectors and yeast host strains have been instrumental in work that has led to countless discoveries in recent decades.

Blood platelets have one main job: Stop bleeding by forming clots. Sometimes, however, these tiny cell fragments fail when they are needed most – when a person is experiencing massive bleeding, usually due to trauma. Dr. Christian Kastrup developed a potential strategy for endowing platelets with extra powers so they can rise to the occasion and continue coagulation. If it’s proven to work in clinical situations, such “superplatelets” might become a standard part of emergency department supplies, along with bandages, oxygen, and saline. The research was described in the Journal of Thrombosis and Haemostasis.

Dr. Brett Finlay, was inducted into the Canadian Medical Hall of Fame in 2018. This prestigious honour is added to the collection of awards that he has received for his contributions to understanding disease and improving people’s health. Dr. Finlay's research on how microbes interact with humans to cause health and disease have led to human and animal vaccines, including a bovine vaccine to E-coli, as well as fundamental changes in our conceptions of health.

In 2018, Dr. Charles Haynes was elected as a Fellow into the Canadian Academy of Engineering for his distinguished achievements and career-long service to the engineering profession. Election to the CAE is one of the highest professional honours an engineer in Canada can receive.

Plant Responses To Eliminate Critical Threats (PRoTECT) is a first-rate international training program designed to foster collaborative, multidisciplinary, and interdisciplinary research, and prepare the next generation of scientists for internationally-competitive positions. The program is hosted by UBC in Canada and the Georg-August-University Göttingen in Germany, with the UBC team led by Drs. Xin Li and Jim Kronstad. The program is jointly supported by a $1.65 million award (over six years) from the Natural Sciences and Engineering Research Council of Canada (NSERC) through its Collaborative Research and Training Experience (CREATE) initiative and the Deutsche Forschungsgemeinschaft International Research Training Groups (DFG-IRTG). 

Dr. Stephen Withers and collaborators have identified a new, more powerful group of enzymes that can turn any type of blood into the universally usable type O, expanding the pool of potential blood donors and making blood matching safer and easier. The results of this study were presented at the National Meeting & Exposition of the Americal Chemical Society (ACS) in Boston, MA.

Canada Research Chairs improve our depth of knowledge and quality of life, strengthen Canada's international competitiveness, and help train the next generation of highly-skilled people through student supervision, teaching and the coordination of other researchers' work. On November 13, 2018, it was announced that Dr. Peter Zandstra was awarded the CIHR Tier 1, Canada Research Chair in Stem Cell Bioengineering.  

Dr. Peter Zandstra, Director of UBC’s Michael Smith Laboratories and School of Biomedical Engineering , co-founds biotech company Notch Therapeutics with Dr. Juan Carlos Zúñiga-Pflücker, which develops stem-cell derived immunotherapies with a focus on cancer treatment. As Notch’s Chief Scientific Officer, Dr. Zandstra and the Notch team build technology that produces an unlimited supply of custom designed T cells and other cell types for treatment of various diseases. They later went on to secure $85 million in financing.

Dr. Brett Finlay teamed up with his daughter, Dr. Jessica Finlay, a recognized environmental gerontologist, to write a book that explores how aging affects the human microbiome. Using scientific fact to highlight the connection between microbes and quality of health, The Whole-Body Microbiome dispels common health myths and emphasizes the beneficial impact of seemingly simple lifestyle choices.

Dr. Leonard Foster was recognized for his exceptional mentorship efforts at the UBC Fall 2019 Graduation Ceremony where he was presented with a 2019 Killam Award for Excellence in Mentoring. The Killam Awards for Excellence in Mentoring recognize faculty members with outstanding ability to foster the intellectual, professional, and personal development of graduate students. Award winners encourage, inspire, and support students to reach their fullest potential in ways that are tailored to each individual. This award acknowledges Dr. Foster’s co profound impact on innumerable students, postdoctoral fellows, staff, and colleagues.

Since the emergence of the COVID-19 pandemic, the work of MSL faculty has been instrumental in understanding and combatting the virus. Much of the progress made through variant sequencing, vaccine development and life-saving treatments have roots in research carried out within the within the MSL. Highlights of the significant contributions made to the global effort to curb the pandemic include: 

March 2020  
AbCellera and Eli Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19 

April 2020
Drs Wilfred Jefferies, Leonard Foster and team secure MSFHR funding to develop potential COVID-19 vaccines via the Novel COVID-19 Vaccine Initiative 

May 2020 
Dr. Martin Hirst, Thibault Mayor and other UBC researchers collaborate to address the COVID-19 testing challenge 

June 2020  
Dr. Terry Snutch Leads Canadian Researchers in Sequencing Covid-19 Virus Genome 

October 2020
Vaccine expert Dr. Anna Blakney joins Team Halo, an initiative started by the United Nations and Vaccine Confidence Project, which connects scientists and clinicians working on COVID-19 to the general public over TikTok 

December 2020 
Adjunct Professor Carl Hansesn’s company AbCellera makes waves with successful IPO 

Dr. Martin Hirst’s lab pilots new COVID-19 testing and cleaning protocols 

April 2021 
Dr. Leonard Foster speaks on how cloud computing support accelerates COVID-19 vaccine improvements 

Dr. Wilfred Jefferies collaborates with Eyam Vaccines and Immunotherapeutics on COVID-19 vaccine pre-clinical trials 

Professor Wilfred Jefferies’ innovative strategies and outstanding inventions that enable cancer immunotherapies and vaccines have been recognized with his induction as a Fellow of the National Academy of Inventors (NAI).  Election as a Fellow of the NAI is the highest professional distinction accorded solely to eminent academic inventors. Jefferies is the first Canadian immunologist to be inducted into the NAI.

Internationally recognized as a leader in biomedical engineering and stem cell therapeutics, Dr. Peter Zandstra is inducted as a Fellow of the Canadian Academy of Health Sciences (CAHS). The CAHS Fellowships aim to recognize Canadian scientists who demonstrate “...vision, innovation and sustained excellence in their fields”. Dr. Zandstra’s research on stem cell maturation is at the forefront of the development of innovative stem cell therapeutics for diseases such as leukemia. This induction by the CAHS recognizes his contributions to the growth of biomedical engineering research and education in Canada.

Dr. Anna Blakney is jointly appointed as Assistant Professor to the Michael Smith Laboratories and the School of Biomedical Engineering. Her research focuses on the development of new biotechnologies with particular interest in applying cell biology and materials sciences to the engineering of vaccine formulations that deliver self-amplified RNA. An active and impactful science communicator and educator, Dr. Blakney joined Team Halo, an initiative started by the United Nations and Vaccine Confidence Project, which connects scientists and clinicians working on COVID-19 to the general public over TikTok. 

Dr. Sabrina Leslie is jointly appointed as Associate Professor to the Michael Smith Laboratories and the Department of Physics and Astronomy. Dr. Leslie uses single-molecule microscopy to measure biomolecular interactions in the complex and stochastic environments of living cells in real-time. Her innovative research, like the invention of the Convex Lens-Induced Confinement (CLiC) imaging platform, contribute new biotechnologies and therapies that help to understand, identify, and combat both emerging and known diseases. 

Dr. Anna Blakney receives a Michael Smith Foundation for Health Research (MSFHR) Scholar Award for her work with RNA vaccines and therapies.  This MSFHR award supports early career researchers in developing their own research teams and programs working with innovative healthcare solutions. The annual award contributes $90,000 for five years towards expanding Dr. Blakney’s research program which investigates the interactions between RNA, biomaterials and the immune system and harnesses this knowledge to design next generation RNA vaccines and therapies. 

Dr. Terry Snutch is awarded the prestigious 2021 Bill and Marilyn Webber Lifetime Achievement Award by UBC’s Faculty of Medicine. This award recognizes extraordinary members who have had sustained and distinguished careers at UBC in the areas of research, teaching and service. A long-serving faculty member at UBC since 1989, Dr. Snutch is regarded internationally as a foremost expert and pioneer in molecular neurobiology. His significant contributions in the areas of neuronal physiology, pathophysiology and therapeutic intervention define an exemplary career that demonstrates his excellence in research, teaching and impactful transformations to health care. 

Dr. Peter Zandstra is appointed as a Member of the Order of Canada for his "pioneering leadership in the field of stem cell bioengineering and its subsequent innovative health and economic impacts.” This honour is bestowed upon Canadians that “…make extraordinary contributions to the nation.” As Director of both the Michael Smith Laboratories and the School of Biomedical Engineering, Dr. Zandstra has made enormous inroads into stem cell derived immunotherapies for chronic diseases. He is also the co-founder of the two biotechnology companies, ExCellThera and Notch Therapeutics. With over two decades of groundbreaking work in the fields of biotechnology and regenerative medicine, this appointment recognizes both Zandstra’s accomplishments and his contributions to the future health of Canadians.

Dr. Martin Hirst has been a faculty member since 2015 when UBC’s Centre for High-Throughput Biology (CHiBi) merged with the MSL. His research focuses on understanding the role of the epigenome in normal development and disease while aiming to improve health outcomes for Canadians. Cross appointed with the Department of Microbiology and Immunology and Canada’s Michael Smith Genome Sciences Centre, Dr. Hirst brings a wealth of experience in genomic research and technology to his leadership role.

Dr. Xin Li is nominated as a Tier 1 Canada Research Chair in Plant Immunity. A world-renowned expert in plant immunity and member of the MSL since 2001, Dr. Li has two main branches of research. Her work focuses on how plants’ immune systems recognize and respond to pathogens, as well as how fungal pathogens develop and cause damage to their hosts. Dr. Li is also central to is the Plant Responses To Eliminate Critical Threats (PRoTECT) program, bridging research from the University of British Columbia and the Georg-August-University Göttingen in Germany. Dr. Li’s research is essential for various aspects of food security and improving crop protection strategies globally. 

Dr. Marco Todesco joins the MSL as an Assistant Professor in the field of Plant Bioengineering, jointly joint appointed with the Department of Botany and the Department of Biology, Irving K. Barber Faculty of Science UBC Okanagan. His research program uses a combination of molecular and developmental biology, quantitative genetics, genomics and field experiments to identify the genetic and molecular basis of diversity and adaptation in plants, with the goal of translating this knowledge towards crop improvement. 

Renowned genome scientist and cancer researcher Dr. Marco Marra joins the MSL as a Professor, cross appointed with UBC’s Department of Medical Genetics and holding a Canada Research Chair in Genome Science. Using a combination of bioinformatics, genomics, genetics and cell biology, the Marra lab reveals key insights about cancer cell vulnerabilities, with the intention of exploiting them to improve treatment outcomes for cancer patients. Dr. Marra’s research has also contributed to the Human Genome Project, the sequencing of the SARS coronavirus genome, and the application of whole genome analyses for personalized cancer medicine. 

Dr. Anna Blakney is nominated as a Tier 2 Canada Research Chair in Nucleic Acid Bioengineering. Dr. Blakney’s research program is working at the forefront of RNA technology exploration and application, developing next-generation RNA vaccines and therapies. During her PhD, Dr. Blakney was part of a team that developed a self-amplifying RNA vaccine for COVID-19. Now moving beyond COVID-19 treatment and prevention, Dr. Blakney’s lab is exploring applications for mRNA technology in the treatment of ovarian cancer.

Dr. Terrance Snutch is recognized for his outstanding accomplishments in the field of brain research, receiving the prestigious Margolese National Brain Disorders Prize.  With a vast research career spanning over three decades, Dr. Snutch is internationally regarded as a pioneer in the field of molecular neurobiology. As a prolific inventor of novel brain disorder targets and therapeutics, he holds over 100 U.S. and international issued patents. Dr. Snutch receives Canada’s most prestigious award for basic and clinical brain research, for his “…ground-breaking research, drug design and development, and clinical and commercial translation – all directly contributing to treatments for brain disorders”. 

Dr. Peter Zandstra is nominated for the inaugural Scientific Entrepreneurship Award from Life Sciences BC Former Director of the MSL and cross-appointed with the School for Biomedical Engineering, Dr. Zandstra’s work straddles the space between academia and industry. On top of running a stem cell-focused biotechnology research laboratory as a Tier 1 Canada Research Chair in Stem Cell Bioengineering, he has founded several biotechnology companies, including ExCellThera and Notch Therapeutics, both of which have made a significant impact on the design of novel therapeutic technologies.